JP2022535924A5 - - Google Patents
Info
- Publication number
- JP2022535924A5 JP2022535924A5 JP2021572583A JP2021572583A JP2022535924A5 JP 2022535924 A5 JP2022535924 A5 JP 2022535924A5 JP 2021572583 A JP2021572583 A JP 2021572583A JP 2021572583 A JP2021572583 A JP 2021572583A JP 2022535924 A5 JP2022535924 A5 JP 2022535924A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- polypeptide complex
- seq
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050785A JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858254P | 2019-06-06 | 2019-06-06 | |
| US62/858,254 | 2019-06-06 | ||
| US202062978662P | 2020-02-19 | 2020-02-19 | |
| US62/978,662 | 2020-02-19 | ||
| PCT/US2020/036493 WO2020247871A2 (en) | 2019-06-06 | 2020-06-05 | Compositions and methods relating to tumor activated t cell engagers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050785A Division JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535924A JP2022535924A (ja) | 2022-08-10 |
| JP2022535924A5 true JP2022535924A5 (enExample) | 2023-06-09 |
Family
ID=73652312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572583A Pending JP2022535924A (ja) | 2019-06-06 | 2020-06-05 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
| JP2025050785A Pending JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050785A Pending JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20230220105A1 (enExample) |
| EP (1) | EP3980131A4 (enExample) |
| JP (2) | JP2022535924A (enExample) |
| KR (1) | KR20220052898A (enExample) |
| CN (1) | CN114423499A (enExample) |
| WO (2) | WO2020247867A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| US20230220105A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| AU2021326469C1 (en) | 2020-08-11 | 2026-04-30 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| CN114656562B (zh) | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| CN117616137A (zh) * | 2021-05-11 | 2024-02-27 | 佳努克斯治疗公司 | 靶向egfr和cd3的抗体及其用途 |
| AR125758A1 (es) * | 2021-05-12 | 2023-08-09 | Janux Therapeutics Inc | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| EP4519326A4 (en) * | 2022-05-04 | 2026-05-06 | Janux Therapeutics Inc | TUMOR-ACTIVATED MULTISPECIFIC ANTIBODIES TO TARGET CD28 AND PD-L1 AND THEIR METHODS OF USE |
| AR129202A1 (es) * | 2022-05-04 | 2024-07-31 | Janux Therapeutics Inc | Anticuerpos activados por tumores que se dirigen a trop2 y usos de estos |
| CA3264784A1 (en) * | 2022-08-18 | 2024-02-22 | Immunocore Limited | MULTI-DOMAIN BONDING MOLECULES |
| CN121443645A (zh) * | 2023-05-03 | 2026-01-30 | 佳努克斯治疗公司 | 靶向cd3的肿瘤活化的抗体及其用途 |
| WO2025085862A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| CN122459332A (zh) * | 2023-10-20 | 2026-07-24 | 百欧恩泰欧洲股份公司 | 多特异性t细胞衔接体组合物及其使用方法 |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| US20260226165A1 (en) * | 2024-12-17 | 2026-08-06 | Merck Sharp & Dohme Llc | Compositions and methods related to tumor activated molecules targeting nectin-4 and effector cell antigens |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031264A1 (en) * | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| JP2009540015A (ja) * | 2006-06-14 | 2009-11-19 | イムクローン・リミテッド・ライアビリティ・カンパニー | 抗ｅｇｆｒ抗体の凍結乾燥製剤 |
| WO2008119567A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| ES2716864T3 (es) * | 2007-06-06 | 2019-06-17 | Monsanto Technology Llc | Genes y usos para la mejora de plantas |
| TW200944231A (en) * | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2013041865A1 (en) * | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
| PE20150605A1 (es) * | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| US9562110B2 (en) * | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| EP3628328B1 (en) * | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL300408B2 (en) * | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| CN107709356A (zh) * | 2015-06-26 | 2018-02-16 | 南加利福尼亚大学 | 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞 |
| ES3056995T3 (en) * | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| KR102530742B1 (ko) * | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| CN111247171A (zh) * | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| MX2020012217A (es) * | 2018-05-14 | 2021-03-02 | Harpoon Therapeutics Inc | Porción de unión para activación condicional de moléculas de inmunoglobulina. |
| US20230220105A1 (en) * | 2019-06-06 | 2023-07-13 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
-
2020
- 2020-06-05 US US17/616,278 patent/US20230220105A1/en active Pending
- 2020-06-05 US US17/616,281 patent/US20230220109A1/en not_active Abandoned
- 2020-06-05 EP EP20819457.1A patent/EP3980131A4/en active Pending
- 2020-06-05 KR KR1020227000224A patent/KR20220052898A/ko active Pending
- 2020-06-05 CN CN202080056153.1A patent/CN114423499A/zh active Pending
- 2020-06-05 JP JP2021572583A patent/JP2022535924A/ja active Pending
- 2020-06-05 WO PCT/US2020/036489 patent/WO2020247867A2/en not_active Ceased
- 2020-06-05 WO PCT/US2020/036493 patent/WO2020247871A2/en not_active Ceased
-
2024
- 2024-07-26 US US18/785,900 patent/US20240376226A1/en not_active Abandoned
-
2025
- 2025-03-25 JP JP2025050785A patent/JP2025111446A/ja active Pending